Drug Availability Correction

HPS Pharmacies wish to give notice that Pfizer are experiencing a supply interruption for cefalotin vials as follows:

DBL™ Cephalothin Sodium
Cefalotin (as sodium) 1g
ARTG 63203

Normal supplies are expected to resume in early April 2020. Pfizer is currently the only supplier of cefalotin in Australia.

Cefalotin is a moderate-spectrum cephalosporin with a similar spectrum of antibacterial activity to cefazolin. Cefazolin may be considered as a therapeutic alternative in some cases. The Therapeutic Guidelines: Antibiotic favour cefazolin over cefalotin as it is no less effective and has a longer half-life. However, the guidelines note that clinical failures have occurred with cefazolin for the treatment of infections due to Staphylococcus aureus that produce beta-lactamase enzymes that hydrolyse cefazolin but not cefalotin or antistaphylococcal penicillins. The advice of an Infectious Disease Physician should be sought in individual cases.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.